Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Circulating αKlotho influences phosphate handling by controlling FGF23 production.

Smith RC, O'Bryan LM, Farrow EG, Summers LJ, Clinkenbeard EL, Roberts JL, Cass TA, Saha J, Broderick C, Ma YL, Zeng QQ, Kharitonenkov A, Wilson JM, Guo Q, Sun H, Allen MR, Burr DB, Breyer MD, White KE.

J Clin Invest. 2012 Dec;122(12):4710-5. doi: 10.1172/JCI64986. Epub 2012 Nov 26.

2.

Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho.

Hum JM, O'Bryan LM, Tatiparthi AK, Cass TA, Clinkenbeard EL, Cramer MS, Bhaskaran M, Johnson RL, Wilson JM, Smith RC, White KE.

J Am Soc Nephrol. 2017 Apr;28(4):1162-1174. doi: 10.1681/ASN.2015111266. Epub 2016 Nov 11.

PMID:
27837149
3.

αKlotho: FGF23 coreceptor and FGF23-regulating hormone.

Jüppner H, Wolf M.

J Clin Invest. 2012 Dec;122(12):4336-9. doi: 10.1172/JCI67055. Epub 2012 Nov 26.

4.

Pathogenic role of Fgf23 in Dmp1-null mice.

Liu S, Zhou J, Tang W, Menard R, Feng JQ, Quarles LD.

Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E254-61. doi: 10.1152/ajpendo.90201.2008. Epub 2008 Jun 17.

5.

Novel functions of circulating Klotho.

Hum JM, O'Bryan L, Smith RC, White KE.

Bone. 2017 Jul;100:36-40. doi: 10.1016/j.bone.2016.11.025. Epub 2016 Nov 23. Review.

PMID:
27890549
6.

Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.

Martin A, Liu S, David V, Li H, Karydis A, Feng JQ, Quarles LD.

FASEB J. 2011 Aug;25(8):2551-62. doi: 10.1096/fj.10-177816. Epub 2011 Apr 20.

7.

Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.

Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Jüppner H, Jonsson KB.

Endocrinology. 2004 Jul;145(7):3087-94. Epub 2004 Feb 26.

PMID:
14988389
8.

The parathyroid is a target organ for FGF23 in rats.

Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J.

J Clin Invest. 2007 Dec;117(12):4003-8.

9.

FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone.

Wöhrle S, Bonny O, Beluch N, Gaulis S, Stamm C, Scheibler M, Müller M, Kinzel B, Thuery A, Brueggen J, Hynes NE, Sellers WR, Hofmann F, Graus-Porta D.

J Bone Miner Res. 2011 Oct;26(10):2486-97. doi: 10.1002/jbmr.478.

10.
11.

Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.

Martin A, David V, Li H, Dai B, Feng JQ, Quarles LD.

Mol Endocrinol. 2012 Nov;26(11):1883-95. doi: 10.1210/me.2012-1062. Epub 2012 Aug 28.

12.

Bone-kidney axis in systemic phosphate turnover.

Razzaque MS.

Arch Biochem Biophys. 2014 Nov 1;561:154-8. doi: 10.1016/j.abb.2014.06.031. Epub 2014 Jul 2. Review.

PMID:
24997362
13.

A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.

Ichikawa S, Austin AM, Gray AK, Econs MJ.

J Bone Miner Res. 2012 Feb;27(2):453-60. doi: 10.1002/jbmr.544.

14.

Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation.

Farrow EG, Summers LJ, Schiavi SC, McCormick JA, Ellison DH, White KE.

J Endocrinol. 2010 Oct;207(1):67-75. doi: 10.1677/JOE-10-0181. Epub 2010 Jul 30.

15.

FGF23 regulates renal sodium handling and blood pressure.

Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, Pohl EE, Erben RG.

EMBO Mol Med. 2014 Jun;6(6):744-59. doi: 10.1002/emmm.201303716. Epub 2014 Apr 6.

16.

1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport.

Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, Collins JF, Haussler MR, Ghishan FK.

Am J Physiol Gastrointest Liver Physiol. 2005 Dec;289(6):G1036-42. Epub 2005 Jul 14.

PMID:
16020653
17.
18.

Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.

Karaplis AC, Bai X, Falet JP, Macica CM.

Endocrinology. 2012 Dec;153(12):5906-17. doi: 10.1210/en.2012-1551. Epub 2012 Oct 4.

19.

Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.

Quarles LD.

Exp Cell Res. 2012 May 15;318(9):1040-8. doi: 10.1016/j.yexcr.2012.02.027. Epub 2012 Mar 7. Review.

20.

Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo.

Rhee Y, Bivi N, Farrow E, Lezcano V, Plotkin LI, White KE, Bellido T.

Bone. 2011 Oct;49(4):636-43. doi: 10.1016/j.bone.2011.06.025. Epub 2011 Jun 25.

Supplemental Content

Support Center